Table 1.
Patient demographics and baseline characteristics
| Regorafenib 160 mg starting dose | ||
|---|---|---|
| (N = 15) | ||
| n (%) | ||
| Sex | Male | 11 (73) |
| Female | 4 (27) | |
| European Cooperative Oncology Group performance status | 0 | 12 (80) |
| 1 | 3 (20) | |
| Tumor site | Pancreatic ductal adenocarcinoma | 6 (40) |
| Pancreatic neuroendocrine tumor | 1 (7) | |
| Carcinoid tumor | 2 (13) | |
| Gastric cancer (adenocarcinoma) | 1 (7) | |
| Small-intestine carcinoma | 1 (7) | |
| Penile carcinoma | 1 (7) | |
| Cholangiocarcinoma | 1 (7) | |
| Submandibular-gland neoplasm | 1 (7) | |
| Urothelial tumor | 1 (7) | |
| Previous anticancer therapy | Systemic therapya | 13 (87) |
| Surgery | 12 (80) | |
| Radiotherapy | 3 (20) | |
| Number of previous chemotherapy regimens | 0 | 2 (13) |
| 1 | 5 (33) | |
| 2 | 6 (40) | |
| 3 | 1 (7) | |
| 4 | 1 (7) |
aSystemic therapy included S-1 (n = 9), gemcitabine (n = 9), platinum compounds (n = 5), 5-fluorouracil (n = 3), taxanes (n = 2), and irinotecan (n = 1); patients may have had more than one type of chemotherapy either in combination or as separate lines of treatment